CAR-T Referral Process: Insights from UCSF : Episode 9
CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways
Panelists discuss how UCSF Health has learned that successful integration of CAR T-cell therapy in multiple myeloma requires multidisciplinary collaboration, patient selection optimization, and management of toxicities. Future research includes exploring CAR T-cell therapy in earlier treatment lines and combining it with novel agents to enhance efficacy.
EP: 1.Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma
EP: 2.Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment
EP: 3.Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
EP: 4.Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection
EP: 5.CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
EP: 6.Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers
EP: 7.Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies
EP: 8.Example of Successful Collaboration with a Referring Community Practice
Now Viewing
EP: 9.CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways
Video content above is prompted by the following:
- What are the most important lessons your institution has learned in the integration of CAR T-cell therapy into the multiple myeloma treatment landscape?
- Looking ahead, what are your institution’s plans or considerations for further expanding the role of CAR T-cell therapy in earlier lines of multiple myeloma treatment?
Recent Videos
Related Content
